Mass. startup gets $30M boost to advance gene regulators

04/12/2013 | American City Business Journals · Xconomy

A Series A funding round led by Arch Venture Partners and Flagship Ventures has brought in $30 million to Syros Pharmaceuticals, which is developing treatment techniques based on advanced genetic sequencing and insights into how proteins control genetic expression in stem cells. The Watertown, Mass.-based biotech startup will use the money to expedite the discovery and development of proteins it calls super enhancers.

View Full Article in:

American City Business Journals · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX